SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalMunch-a-Biotech Today


Previous 10 Next 10 
To: DewDiligence_on_SI who wrote (3121)1/31/2018 11:51:27 PM
From: Miljenko Zuanic
   of 3158
 
<The 10b5-1 plan VRTX is talking about in the PR is for the company's own buybacks on the open market;.

I guess, I did not read this correctly in first place. Are you saying that company as entity can have their own ?

northerntrust.com

I am confused here. Why company, as entity, can not do buy back on "as seen fit" schedule, even when they have material information? For instance, price is underappreciated, and they have positive data on candidate (that can paint business picture more pink)?

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Miljenko Zuanic who wrote (3123)2/1/2018 8:14:37 AM
From: DewDiligence_on_SI
   of 3158
 
Yes, it's the company's own 10b5-1 (buying) plan. It's not necessary to have a 10b5-1 plan to buy company shares on the open market, but some companies prefer to set up a 10b5-1 with an investment bank, rather than handling the task internally, to remove any appearance of impropriety.

Share RecommendKeepReplyMark as Last Read


From: nigel bates2/16/2018 5:20:43 AM
   of 3158
 
Sanofi further committing to develop nanobodies with Ablynx:

GHENT, Belgium, 16 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that Sanofi has exercised its option to license two additional target combinations as part of the research collaboration signed in July 2017, focussed on developing and commercialising Nanobody®-based therapeutics for the treatment of various immune-mediated inflammatory diseases.
Under the terms of the agreement, Sanofi gains exclusive global rights to two additional multi-specific Nanobodies against selected targets and in return will pay Ablynx exercise fees totalling €13 million plus additional research funding. Multi-specific Nanobodies provide the ability to address different pathway or disease targets with one therapeutic molecule. Ablynx has already received an upfront payment totalling €23 million, together with research funding under this collaboration.
Sanofi will be responsible for the development, manufacturing and commercialisation of any products resulting from this agreement comprising up to eight programmes. Ablynx will be eligible to receive development, regulatory and commercial milestone payments of up to €2.4 billion plus tiered royalties up to low double digits on the net sales of any products originating from the collaboration...

Share RecommendKeepReplyMark as Last Read


From: tuck6/19/2018 11:32:53 AM
   of 3158
 
Roche taking out Foundation Medicine (FMI).

Cheers, Tuck

Share RecommendKeepReplyMark as Last Read


From: nigel bates8/9/2018 10:05:40 AM
1 Recommendation   of 3158
 
This is perhaps more interesting than the size of the deal would suggest. (And the net cost is even lower.)
Vernalis had some interesting IP.

Ligand Pharmaceuticals Incorporated (LGND) and Vernalis plc (VER.L) announce that Ligand has declared its firm intention to acquire the entire issued and to be issued shares of Vernalis through a UK scheme of arrangement conditional on approval by the Vernalis shareholders. Vernalis is a structure-based drug discovery biotechnology company with a broad pipeline of partnered programs and ongoing collaborations.

Under the terms of the proposed UK scheme of arrangement, Ligand would pay Vernalis shareholders £0.062 per share in cash, valuing Vernalis at approximately £32.8 million, equivalent to approximately $43 million. This proposal – which requires approval by a majority of the shareholders representing at least 75% or more in value of the company’s outstanding shares voting on the transaction – has received the support and irrevocable undertakings from the Board of Directors of Vernalis and its two largest shareholders, who own in aggregate approximately 67% of the outstanding shares of the company.

On March 15, 2018 Vernalis announced that as part of its then-ongoing strategic review, it had decided to commence a formal sales process with Evercore serving as financial advisor. As part of its strategic review Vernalis has substantially completed the closure of its US commercial operations and remains on track to have completed this by 30 September 2018. If Ligand’s offer is approved by Vernalis shareholders, the transaction is expected to close in October 2018.

The acquisition of Vernalis would provide Ligand with the following:

A portfolio of more than 8 fully-funded partnered programs, or shots on goal, including programs in the respiratory, oncology and CNS sectors. Partners include Corvus, Verona, Celgene, Servier, Menarini, Tris and CTI.
A 70-person R&D team based in Cambridge, England focused on fragment- and structure-based drug discovery and partnering, with an active portfolio of collaboration agreements generating over $8 million per year of service revenue matched by a comparable level of costs, and partnerships that have the potential to generate additional near-term shots on goal. Ongoing collaboration partners include Servier, Daiichi Sankyo, Lundbeck, Asahi Kasei and an undisclosed Japanese partner.
An established compound library and additional early-stage, unpartnered programs in oncology, CNS and other areas that will provide business development out-licensing and corporate formation opportunities.
Expected cash on hand as of June 30, 2018 of £27.3 million or approximately $36 million. Ligand estimates incurring additional deal costs of approximately $4 million, resulting in $32 million of net cash to Ligand from the transaction.
United Kingdom-based operations that would provide a platform to more efficiently pursue investment and acquisition opportunities in Europe and the United Kingdom.

Share RecommendKeepReplyMark as Last Read


From: nigel bates10/18/2018 5:10:18 AM
   of 3158
 
Endocyte / Novartis:

WEST LAFAYETTE, Ind., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for cancer treatment, today announced that it has entered into an agreement and plan of merger with Novartis AG (“Novartis”) pursuant to which Novartis will acquire Endocyte for $24 per share, or a total equity value of approximately $2.1 billion, in cash. This offer represents a premium of 54% percent to Endocyte’s closing price of $15.56 on October 17, 2018. The transaction was unanimously approved by the board of directors of Endocyte.

“Since acquiring exclusive worldwide rights to develop and commercialize PSMA-617 agents in 2017, the entire Endocyte team, along with our partners, have worked tirelessly to build a leading radioligand (RLT) portfolio and create value for patients and shareholders alike. We are thrilled that Novartis recognizes the potential for 177Lu-PSMA-617 to change the treatment landscape for men with metastatic castration-resistant prostate cancer (mCRPC), as well as the broader role that RLTs may potentially play in the treatment of cancer,” said Mike Sherman, president and CEO of Endocyte. “The global reach and expertise of Novartis in developing and commercializing RLT therapies will be critical in efforts for patients to benefit from these therapies as quickly as possible.”

Share RecommendKeepReplyMark as Last Read


From: nigel bates10/29/2018 8:31:02 AM
   of 3158
 
STOCKHOLM (Reuters) - Private equity firm EQT on Monday made a recommended 5.97 billion Swedish crown (509.52 million pounds)cash bid to buy Swedish speciality pharma group Karo Pharma (KARO.ST).

The offer, made by the EQT VIII fund and unanimously recommended by Karo Pharma's board, represents a 25.3 percent premium to Karo's closing price on Friday.

"We are delighted that the Board of Directors has decided to recommend EQT VIII's offer," EQT partner Per Franzen said in a statement.

"We are impressed by Karo Pharma's development and successful strategic transformation from an early stage research and development company into a leading speciality pharmaceutical company with a strong product portfolio and European reach."

EQT said that Karo Pharma Chairman Anders Lonner and board member Per-Anders Johansson, together representing in total 13.6 percent of shares and votes in the company, had declared they intended to accept the bid.

The acceptance period is expected to run between Nov. 13 and Dec. 10 and requires EQT to take ownership of 90 percent of the shares. It said it does not currently own or control any shares in Karo Pharma.

Share RecommendKeepReplyMark as Last Read


From: nigel bates11/20/2018 5:43:44 AM
   of 3158
 
Reuters) - U.S. medical device maker Boston Scientific Corp (BSX.N) said it had agreed a 3.3 billion pound cash deal to buy Britain's BTG Plc (BTG.L) to bolster its capabilities in interventional medicine.

The offer of 840 pence per share represents a premium of 36.6 percent to BTG's close of 615 pence on Monday.

Shares of BTG soared more than 35 percent to 832 pence, their highest level since Jan. 2015, on Tuesday. Up to Monday's close, the stock had slipped 19.3 percent this year.

Boston Scientific said BTG's interventional portfolio - using devices to deliver drugs to affected organs - would augment its capabilities in important areas of unmet need such as cancer and pulmonary embolism.

BTG, which has long produced drugs to treat overdoses and rattlesnake bites, has focussed on interventional medicine in recent years, for example producing beads that target tumours.

Boston Scientific's chairman and CEO Michael F. Mahoney said the addition of these therapies to our portfolio would ultimately advance patient care in ways that could not be realised by either company alone, while also providing a strong return for investors.

BTG said it considered the terms of the offer to be fair and reasonable and it planned to recommend the deal to shareholders.

Share RecommendKeepReplyMark as Last Read


From: tuck12/3/2018 9:32:32 AM
   of 3158
 
GSK takes out Tesaro (TSRO). I don't get it. They seem to me like something of an also ran in the PARP space. Whatever, sector could use the boost.

Cheers, Tuck

Share RecommendKeepReplyMark as Last Read


From: tuck1/3/2019 8:53:42 AM
1 Recommendation   of 3158
 
BMY takes out Celgene for 1 BMY share + $50 per share of CELG. About $102/share. Might juice the sector on what's shaping up to be bad Apple day.

Celgene Munch

Cheers, Tuck

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10